🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in the Netherlands / NCT05800093
Active, not recruiting Observational

Proteomics and Genomics Combined With CT to Predict CVD

NCT05800093 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2023-01-12
Last updated
2025-10-02

Condition(s) studied

Coronary Artery Disease Progression

Study summary

This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.

Eligibility

Sex
ALL
Min age
50 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients between 50 and 75 years old * Subjects at intermediate to high risk for ASCVD * Asymptomatic patients without cardiac chest pain * Evidence of atherosclerosis on baseline CCTA Exclusion Criteria: * Renal insufficiency, defined as eGFR \< 30 ml/min * History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke) * Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy * Change in lipid lowering therapy in the last 6 months * Use of more than two antihypertensive agents * No coronary atherosclerosis at baseline imaging * Active malignancy requiring treatment * Atrial fibrillation * Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Amsterdam UMC, location AMC Amsterdam Netherlands

More Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05800093 on ClinicalTrials.gov ↗ ← All trials in the Netherlands